Advertisement
GLAGOV results boost hopes for coming outcome trials
Celecoxib is noninferior to naproxen and ibuprofen in cardiac safety
Pioneer of angioplasty never stopped innovating and teaching
Dr. Steven Nissen shares why these studies matter
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
A veteran academic research organization finds its mission more critical than ever
Also finds PCSK9 inhibitor more potent than ezetimibe in statin-intolerant patients
Trial stopped early after evacetrapib fails to budge event rate
Not all coronary calcium is the same, analysis shows
New Scientific Statement From ADA & AHA Says It Should Be Considered Sooner For Obese Patients
A checklist of the latest evidence to share with patients
Advertisement
Advertisement